AI 'Depression Thermometer' Detects Relapses Before They Worsen

Hope Therapeutics has teamed up with Emobot Health to introduce an AI-driven tool for tracking depression and mood disorders. The system, called the 'Depression Thermometer,' works silently in the background of a patient's smartphone. It aims to fill a major gap in treatment-resistant depression (TRD) care by detecting relapses early—before they become severe. The Emobot platform replaces traditional questionnaires with passive monitoring. It analyses facial expressions, vocal tones, and movement patterns without requiring any input from the user. Patients receive real-time updates on their mood and activity through the app, with alerts and appointment scheduling if signs of relapse appear.

Clinical tests show the technology aligns closely with standard depression scales. It matches the MADRS scale with a correlation of 0.89 and the PHQ-9 with 0.83, meaning it reliably tracks changes in a patient's condition. Jonathan Javitt, CEO of Hope Therapeutics, described the system as a '360-degree view' of emotional health, providing clinicians with continuous, objective data. The partnership focuses on a critical issue in TRD: around half of patients relapse within six to twelve months, often between clinic visits. By catching early warning signs, the system could double success rates through timely interventions like ketamine or TMS therapy. The goal is to shift patients from passive recipients of care to active participants in their recovery.

The integration of Emobot's AI into Hope Therapeutics' clinics marks a move toward data-driven mental health care. Patients will have access to personalised insights, while clinicians gain tools to intervene before relapses worsen. The system's ability to track mood continuously could change how depression is managed long-term.